Class summary at a glance.

Every drug in the Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $42485combined across class
Total Rx claims: 14— unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Palivizumab

Brand: Synagis · 14 Part D claims (CY24) · First FDA approval: 1998-06-19

Brand-only (no generics) Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $42485

Class share

100%

of class CY24 spend

View profile →

Clesrovimab

Brand: ENFLONSIA · — Part D claims (CY24) · First FDA approval: 2025-06-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nirsevimab

Brand: BEYFORTUS · — Part D claims (CY24) · First FDA approval: 2023-07-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.